AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52 weeks (group A, n = 33)
Number of subjects: 64
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52-72 weeks (group B, n = 31)
Number of subjects: 64
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (n=64)
Number of subjects: 64
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RVR at 4 weeks
Number of subjects: 64
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with early virologic response from 8‐12 weeks
Number of subjects: 64
Study 21221804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with late virologic response from 16‐24 weeks
Number of subjects: 64
Study 18828055 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose ceftriaxone
Number of subjects: 200
Study 18828055 — intervention group
Group type: COMPARATOR
Intervention: Combination of ampiclox, gentamicin, and metronidazole
Number of subjects: 200
Study 16497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (smokers) - 22 participants
Number of subjects: 121
Study 16497600 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (smokers) - 31 participants
Number of subjects: 121
Study 16497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (never-smokers) - 24 participants
Number of subjects: 121
Study 16497600 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (never-smokers) - 32 participants
Number of subjects: 121
Study 12971972 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b 5 MU daily for 4 weeks, 5 MU tiw for 20 weeks, followed by 3 MU tiw for additional 24 weeks combined with ribavirin 1000-1200 mg/d plus amantadine sulphate 100 mg bid for 48 weeks
Number of subjects: 225
Study 12971972 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha/ribavirin alone
Number of subjects: 225
Study 11115443 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV plus standard care
Number of subjects: 52
Study 11115443 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 52
Study 9083317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping membranes
Number of subjects: 150
Study 9083317 — intervention group
Group type: COMPARATOR
Intervention: Control (Bishop score only)
Number of subjects: 150
Study 8257235 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6 benzo-alpha-pyrone (56 BaP)
Number of subjects: 40
Study 8257235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 40
Study 8257235 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 56 BaP and DEC
Number of subjects: 40
Study 3898285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (1 mg/kg daily i.m. for 2 weeks, then 1 mg/kg 3 times weekly for 10 weeks)
Number of subjects: 9
Study 3898285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 9
Study 3898285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31452319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (Ecu)
Number of subjects: 27
Study 31452319 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 30502307 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 (usual care)
Number of subjects: 631
Study 30502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 (oral anticoagulation prescription tool and patient education)
Number of subjects: 631
Study 30502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 (oral anticoagulation prescription tool, patient materials, educational session, and follow-up clinic)
Number of subjects: 631
Study 30502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 vs Phase 2
Number of subjects: 631
Study 30502307 — intervention group
Group type: COMPARATOR
Intervention: Phase 1
Number of subjects: 631
Study 30502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2
Number of subjects: 631
Study 30502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3
Number of subjects: 631
Study 26576937 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention for knee extension over 12 weeks
Number of subjects: 11
Study 26380361 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training at the workplace for 20 minutes, three times per week
Number of subjects: 18
Study 23946704 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil once daily for 4 weeks
Number of subjects: 114
Study 23946704 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 4 weeks
Number of subjects: 114
Study 21251795 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration
Number of subjects: 20
Study 21251795 — intervention group
Group type: COMPARATOR
Intervention: Matched-placebo administration
Number of subjects: 20
Study 21251795 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration in high PCS scorers
Number of subjects: 20
Study 21251795 — intervention group
Group type: COMPARATOR
Intervention: Matched-placebo administration in high PCS scorers
Number of subjects: 20
Study 21251795 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release opioid administration in low PCS scorers
Number of subjects: 20
Study 21251795 — intervention group
Group type: COMPARATOR
Intervention: Matched-placebo administration in low PCS scorers
Number of subjects: 20
Study 19091796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg in 4 doses)
Number of subjects: 36
Study 19091796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17205963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in diabetic patients lacking nephropathy
Number of subjects: 858
Study 17205963 — intervention group
Group type: COMPARATOR
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in healthy controls
Number of subjects: 858
Study 17205963 — intervention group
Group type: COMPARATOR
Intervention: 5-leucine repeat CNDP1 genotype (5-5) in healthy controls vs DM cases without nephropathy
Number of subjects: 858
Study 15093907 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (50.4 Gy in 28 fractions)
Number of subjects: 203
Study 15093907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (64.8 Gy in 36 fractions)
Number of subjects: 203
Study 11514072 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with schizophrenia
Number of subjects: 0
Study 11514072 — intervention group
Group type: COMPARATOR
Intervention: Patients with schizophrenia
Number of subjects: 0
Study 11514072 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 9627294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepracoat (HAL-C) solution
Number of subjects: 277
Study 9627294 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo)
Number of subjects: 277
Study 7887100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen
Number of subjects: 47
Study 7887100 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen (control)
Number of subjects: 47
Study 3269505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses with varying water content
Number of subjects: 6
Study 31985862 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centred empowerment program
Number of subjects: 70
Study 30699073 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain group (n=17)
Number of subjects: 34
Study 30699073 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 34
Study 28130659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1-4 mg once daily
Number of subjects: 0
Study 28130659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0
Study 28130659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin with lifestyle modification advice
Number of subjects: 0
Study 28130659 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0
Study 26440236 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane-fentanyl based technique
Number of subjects: 76
Study 26440236 — intervention group
Group type: COMPARATOR
Intervention: Total IV anesthesia (TIVA)
Number of subjects: 76
Study 23541248 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 20
Study 23541248 — intervention group
Group type: COMPARATOR
Intervention: Multi-port surgery
Number of subjects: 20
Study 21289249 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) daily dosing (1,600 IU)
Number of subjects: 64
Study 21289249 — intervention group
Group type: EXPERIMENTAL
Intervention: D(3) monthly dosing (50,000 IU)
Number of subjects: 64
Study 21289249 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) dosing
Number of subjects: 64
Study 21289249 — intervention group
Group type: EXPERIMENTAL
Intervention: D(3) dosing
Number of subjects: 64
Study 21289249 — intervention group
Group type: EXPERIMENTAL
Intervention: D(2) or D(3) dosing (1,600 IU daily or 50,000 IU monthly)
Number of subjects: 64
Study 19053979 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 624
Study 19053979 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 190 mg
Number of subjects: 624
Study 19053979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 18043303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 55
Study 18043303 — intervention group
Group type: COMPARATOR
Intervention: Usual activity
Number of subjects: 55
Study 15449756 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 15449756 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 0
Study 12699795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavaterm thermal balloon endometrial ablation system
Number of subjects: 72
Study 12699795 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 72
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2
Number of subjects: 12
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 12246
Number of subjects: 12
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: L. rhamnosus LGG
Number of subjects: 12
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: L. delbrueckii subsp. lactis CHCC 2329
Number of subjects: 12
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: L. casei subsp. alactus CHCC 3137
Number of subjects: 12
Study 10543808 — intervention group
Group type: EXPERIMENTAL
Intervention: All selected strains
Number of subjects: 12
Study 7773098 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 88
Study 2197852 — intervention group
Group type: COMPARATOR
Intervention: Aspartame alone
Number of subjects: 12
Study 2197852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose (3.51 mmol sucrose/kg body wt)
Number of subjects: 12
Study 2197852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame plus sucrose
Number of subjects: 12
Study 376029 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder movement restricted for the first 7 days after operation
Number of subjects: 64
Study 376029 — intervention group
Group type: COMPARATOR
Intervention: Early arm exercises encouraged
Number of subjects: 64
Study 376029 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder immobilization
Number of subjects: 64
Study 30587520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventro-oral thalamotomy
Number of subjects: 171
Study 28126231 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet+EVOO
Number of subjects: 276
Study 28126231 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet+Nuts
Number of subjects: 276
Study 28126231 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 276
Study 26547518 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, nonpharmacologic interventions (MNI)
Number of subjects: 160
Study 26547518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group U)
Number of subjects: 160
Study 24861134 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg loading dose on Day 1 followed by 10 mg once daily for 8 days with a single 25 mg dose of warfarin on Day 4
Number of subjects: 14
Study 24861134 — intervention group
Group type: COMPARATOR
Intervention: Single dose of warfarin on Day 1
Number of subjects: 14
Study 22119181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful awareness in body-oriented therapy (MABT)
Number of subjects: 46
Study 19157816 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity NVP preload (700 poise)
Number of subjects: 31
Study 19157816 — intervention group
Group type: COMPARATOR
Intervention: Medium-viscosity GLM preload (410 poise)
Number of subjects: 31
Study 19157816 — intervention group
Group type: COMPARATOR
Intervention: Low-viscosity CE preload (10 poise)
Number of subjects: 31
Study 18240627 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-Counselling Interview (ECI)
Number of subjects: 200
Study 18240627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 18240627 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study sample
Number of subjects: 200
Study 16234230 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) supplementation
Number of subjects: 72
Study 11988598 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients (n=5)
Number of subjects: 21
Study 11988598 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n=16)
Number of subjects: 21
Study 9816765 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 10158113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (ICD) 2.5 mg before lasing
Number of subjects: 150
Study 10158113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (ICD) 2.5 mg before and after lasing
Number of subjects: 150
Study 10158113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICD)
Number of subjects: 150
Study 30375485 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) applied across the primary motor cortex
Number of subjects: 170000
Study 25853736 — intervention group
Group type: EXPERIMENTAL
Intervention: RNAzol
Number of subjects: 0
Study 25853736 — intervention group
Group type: COMPARATOR
Intervention: RNAzol modified protocol
Number of subjects: 0
Study 24535407 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal whole-body magnetic resonance imaging (wb-MRI)
Number of subjects: 63
Study 24535407 — intervention group
Group type: COMPARATOR
Intervention: Radiological stable disease (MRI-SD)
Number of subjects: 63
Study 23370087 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 66
Study 23370087 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 66
Study 20626052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal point-patch
Number of subjects: 43
Study 20626052 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 43
Study 18311852 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 18311852 — intervention group
Group type: COMPARATOR
Intervention: Established treatment
Number of subjects: 0
Study 17198588 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Tertiary Rehabilitation (STR) including physical therapy and occupational therapy (OT)
Number of subjects: 1209
Study 17198588 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention of internal medicine (Control)
Number of subjects: 1209
Study 12556783 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended current (Group B)
Number of subjects: 186
Study 12556783 — intervention group
Group type: COMPARATOR
Intervention: Pure cutting current (Group A)
Number of subjects: 186
Study 12556783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure cutting followed by blended current (Group C)
Number of subjects: 186
Study 11168329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 88
Study 11168329 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 88
Study 9184780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase mammography screening
Number of subjects: 1144
Study 1289367 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone
Number of subjects: 80
Study 1289367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 80
Study 1289367 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 80
Study 1289367 — intervention group
Group type: COMPARATOR
Intervention: No inotropic support (Control)
Number of subjects: 80
Study 4089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 2.5 mg
Number of subjects: 18
Study 4089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 5 mg
Number of subjects: 18
Study 4089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 10 mg
Number of subjects: 18
Study 4089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 20 mg
Number of subjects: 18
Study 4089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine HCl infusion (0.33G/kg)
Number of subjects: 18
Study 4089188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29483559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mobile coaching (TMC)
Number of subjects: 148
Study 25068802 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 17
Study 25068802 — intervention group
Group type: COMPARATOR
Intervention: SHAM intervention (control)
Number of subjects: 17
Study 24074713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspartate-ornithine granules (6 g bid po)
Number of subjects: 72
Study 24074713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspartate-ornithine granules (3 g bid po)
Number of subjects: 72
Study 21437745 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual oral information plus an information leaflet about SSI (group O/L)
Number of subjects: 207
Study 21437745 — intervention group
Group type: COMPARATOR
Intervention: Usual oral information alone (group O)
Number of subjects: 207
Study 18534421 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable, continuous enhanced circulation therapy (CECT) + low-molecular-weight heparin (LMWH)
Number of subjects: 277
Study 18534421 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 277
Study 16964698 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 50
Study 12803263 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg kg(‐1) followed by 10 mg kg(‐1) h(‐1))
Number of subjects: 40
Study 12803263 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.5 microg kg(‐1) followed by 0.2 microg kg(‐1) min(‐1))
Number of subjects: 40
Study 12119640 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater initial weight loss induced without changes in lifestyle (e.g. liquid formula diets or anorectic drugs)
Number of subjects: 0
Study 12119640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2 years integrated weight maintenance programme consisting of lifestyle interventions (dietary change, nutritional education, behaviour therapy, increased physical activity)
Number of subjects: 0
Study 8682976 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day) + sleep deprivation (6 treatments at 4-5 day intervals)
Number of subjects: 51
Study 8682976 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (150 mg/day)
Number of subjects: 51
Study 1514724 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac
Number of subjects: 47
Study 1514724 — intervention group
Group type: COMPARATOR
Intervention: 100 mg meperidine and 50 mg hydroxyzine
Number of subjects: 47
Study 6487909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 20
Study 6487909 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 20
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs with predicted reduced activity (GSS <1)
Number of subjects: 387
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs with intermediate activity (GSS = 1)
Number of subjects: 387
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs with high activity (GSS >1)
Number of subjects: 387
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy with darunavir/ritonavir or lopinavir/ritonavir
Number of subjects: 387
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal adherence, high predicted RTI activity, or low NRTI mutations
Number of subjects: 387
Study 29575909 — intervention group
Group type: EXPERIMENTAL
Intervention: RTIs with predicted reduced activity
Number of subjects: 387
Study 26671485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 % infiltration at port sites before incision (preincisional)
Number of subjects: 226
Study 26671485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 % infiltration at port sites after trocar removal (preclosure)
Number of subjects: 226
Study 26671485 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration at port sites before incision (preincisional control)
Number of subjects: 226
Study 26671485 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration at port sites after trocar removal (preclosure control)
Number of subjects: 226
Study 25341682 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 32
Study 25341682 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular medical treatment)
Number of subjects: 32